Monoclonal antibody production in large-scale disposable bioreactors

BIOT 154

Donna Giandomenico, Process Development Engineering, Genentech, Inc, 1 DNA Way, MS 208A, So. San Francisco, CA 94080
The use of disposable bioreactors has the potential to increase Genentech's R&D pilot plant capacity, while significantly decreasing installation costs and labor requirements compared to traditional reactor systems. Several studies were performed at scales that ranged from 1 to 400 liters in the WaveŽ bioreactor. Results from large scale monoclonal antibody production demonstrated comparable growth, titer and product quality to that of conventional stainless steel bioreactors.